Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ICP-B381 in advanced solid tumors
CTR20263612Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ICP-B381 in Nonhematologic neoplasms, prostate cancer (PCa), sponsored by Innovent Biologics. Started Sep 2026; status: active.
02
Drugs
ICP-B381
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)
Beyond the preview
Go deeper on CTR20263612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263612.